These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Suchorska B; Giese A; Biczok A; Unterrainer M; Weller M; Drexler M; Bartenstein P; Schüller U; Tonn JC; Albert NL Neuro Oncol; 2018 Jan; 20(2):279-288. PubMed ID: 29016996 [TBL] [Abstract][Full Text] [Related]
7. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
8. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Killela PJ; Pirozzi CJ; Healy P; Reitman ZJ; Lipp E; Rasheed BA; Yang R; Diplas BH; Wang Z; Greer PK; Zhu H; Wang CY; Carpenter AB; Friedman H; Friedman AH; Keir ST; He J; He Y; McLendon RE; Herndon JE; Yan H; Bigner DD Oncotarget; 2014 Mar; 5(6):1515-25. PubMed ID: 24722048 [TBL] [Abstract][Full Text] [Related]
9. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794 [TBL] [Abstract][Full Text] [Related]
10. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
11. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
16. Molecular classification of low-grade diffuse gliomas. Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857 [TBL] [Abstract][Full Text] [Related]
17. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262 [TBL] [Abstract][Full Text] [Related]
18. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842 [TBL] [Abstract][Full Text] [Related]
19. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Olar A; Wani KM; Alfaro-Munoz KD; Heathcock LE; van Thuijl HF; Gilbert MR; Armstrong TS; Sulman EP; Cahill DP; Vera-Bolanos E; Yuan Y; Reijneveld JC; Ylstra B; Wesseling P; Aldape KD Acta Neuropathol; 2015 Apr; 129(4):585-96. PubMed ID: 25701198 [TBL] [Abstract][Full Text] [Related]
20. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]